naturalX Health Ventures

The Schwabe Group, a global pharmaceutical company specializing in plant-based medicines, is the strategic backer and anchor LP. CEO Olaf Schwabe chairs the fund’s Investment Committee, linking portfolio decisions directly to Schwabe’s clinical and manufacturing expertise in natural compounds. This is not a passive family-office allocation; the anchor LP provides scientific diligence infrastructure alongside capital.

The fund deploys €3 million to €5 million per initial investment, reserving up to €10 million for follow-ons. The mandate spans seed through late stage, but the firm states a clear preference for leading Series A and B rounds where companies have demonstrated product-market fit with scientifically-backed health products.

Both. The core activity is direct equity into consumer health startups. In addition, the firm makes LP commitments into external venture funds, allowing it to track a wider funnel of health-tech opportunities while concentrating its own team’s active board work on a curated direct portfolio.

The mandate falls into three overlapping buckets: proactive health (prevention, longevity, sleep, nutrition, supplements, biohacking, genomics, wearables, digital therapeutics, at-home diagnostics, remote care); mental health (digital and alternative approaches, leveraging Schwabe’s plant-based psychiatry heritage); and the broader consumer-health intersection where wellness meets clinical-grade validation.

Sourcing draws on the Schwabe Group’s pharmaceutical network plus the investment team’s own venture relationships in Europe and the US. The diligence process pairs standard VC metrics with Schwabe’s in-house scientific and regulatory capabilities, a model designed to distinguish clinically substantive products from marketing-driven wellness brands. Frequent co-investors such as Earlybird Health and Wellington Partners validate syndicate standards.

Decisions are made by a formal Investment Committee chaired by Schwabe Group CEO Olaf Schwabe. The four-person investment team — Managing Director Marvin Amberg, Investors Clementine Provost and Yang Chen, and Platform Manager Sarah Bossong — prepares and presents opportunities, but the committee structure gives the anchor LP direct governance over capital allocation.

The portfolio spans Europe and the US. Confirmed holdings include companies in Poland (Jutro Medical), Sweden (Flow Neuroscience, Meela Health), Switzerland (mybacs, Kyan Health, Hilo), and the United States (Function Health). The firm’s operational base is Karlsruhe, Germany.